3:54 PM
 | 
May 20, 2019
 |  BC Extra  |  Company News

May 20 Company Quick Takes: LifeArc trades Keytruda royalties for $1.3B; plus Evotec-Just, Actelion-Owlstone, Genomind

LifeArc gets $1.3B for Keytruda royalties
U.K. medical research charity LifeArc sold an undisclosed portion of its royalties for Keytruda pembrolizumab to a subsidiary of the Canada Pension Plan Investment Board for $1.3 billion. LifeArc gained its royalties through a 2007 collaboration with Merck & Co. Inc. (NYSE:MRK) to humanize the IgG4 mAb against PD-1. After selling a smaller portion of its royalty...

Read the full 290 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >